Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Suzhou Hongci Hematology Hospital is a specialized medical institution located in Suzhou, China, dedicated to the diagnosis and treatment of complex blood disorders and hematological malignancies. As a key member of the Hongci Healthcare Group, which is backed by CITIC Pacific, the hospital operates as one of the largest private hematology centers in the Yangtze River Delta region. The facility is renowned for its expertise in hematopoietic stem cell transplantation (HSCT) and the implementation of advanced cell therapies, including CAR-T cell treatments. It integrates clinical care with a robust research framework, serving as a site for numerous clinical trials for innovative oncology and hematology drugs. The hospital provides comprehensive services ranging from intensive chemotherapy to long-term management of bone marrow diseases and rare blood conditions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Suzhou Hongci Hematology Hospital.